Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: Identifying markers for clinical outcome and treatment decisions

PURPOSE: Characterize tumor burden dynamics during PD-1 inhibitor therapy and investigate the association with overall survival (OS) in advanced melanoma. EXPERIMENTAL DESIGN: The study included 107 advanced melanoma patients treated with pembrolizumab. Tumor burden dynamics were assessed on serial...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Nishino, Mizuki, Giobbie-Hurder, Anita, Manos, Michael P., Bailey, Nancy D., Buchbinder, Elizabeth I., Ott, Patrick A., Ramaiya, Nikhil H., Hodi, F. Stephen
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559305/
https://ncbi.nlm.nih.gov/pubmed/28592629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0114
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky